As global economies, and many industries, face uncertain financial situation as a result of the COVID-19 outbreak, the biopharmaceutical industry’s deal making continues with minor disruptions. H1 shows an increase in deal volume, but a decrease in deal value, when compared to the end of 2019. The increase in deal volume was led mainly by global partnerships focused on development and commercialization licensing in the oncology space. Despite an uncertain economy, US IPOs continue to trend upward and Q2 ‘20 saw the highest number of IPOs (value and volume) compared to recent quarters.
Biopharma BD Quarterly Newsletter, 1H 2020
To download the free whitepaper, fill out the form below:
